Citius Pharmaceuticals, Inc.
CTXR evidence brief
What we can confirm
- BioSniper Score:
- 7.3 / 10
- Market Cap:
- $15.2M
- Lead Asset:
- LYMPHIR (Approved)
What it means
What to watch
Prepared research question
What matters most for CTXR—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · CTXR
Citius Pharmaceuticals, Inc. (CTXR) is a biopharmaceutical company whose majority-owned subsidiary, Citius Oncology, markets LYMPHIR (denileukin diftitox-cxdl) for cutaneous T-cell lymphoma, with early commercial revenue and ongoing clinical development.
Key risk: Negative working capital
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate for Citius Pharmaceuticals, Inc..
Similar companies
Citius Pharmaceuticals, Inc. (CTXR) is a biopharmaceutical company whose majority-owned subsidiary, Citius Oncology, markets LYMPHIR (denileukin diftitox-cxdl) for cutaneous T-cell lymphoma, with early commercial revenue and ongoing clinical development.
- Citius Oncology, a majority-owned subsidiary of Citius Pharma, began commercial distribution of LYMPHIR in December 2025 [sec_mda · as of 2026-08-14].
- Product revenues for the nine months ended June 30, 2026 were $7,105,197, with a gross profit of approximately 77% [sec_mda · as of 2026-08-14].
- Cash and equivalents were $17.0 million as of 2026-06-30 [sec].
- An investigator-initiated Phase 1 trial of LYMPHIR in combination with pembrolizumab for gynecologic cancers was presented at ASCO 2026 [news · published 2026-05-26].
- The accumulated deficit was approximately $277.1 million as of June 30, 2026 [sec_mda · as of 2026-08-14].
What works
- LYMPHIR has generated initial commercial revenue with a gross profit margin of approximately 77% for the nine months ended June 30, 2026, and repeat orders from initial accounts [sec_mda · as of 2026-08-14].
- The company expanded its commercial and medical teams in mid-2026, adding 21 field-based professionals and eight medical science liaisons to support clinical engagement [sec_mda · as of 2026-08-14].
- European distribution of LYMPHIR began in April 2026, broadening the geographic market [sec_mda · as of 2026-08-14].
What to weigh
- The company had an accumulated deficit of approximately $277.1 million and negative working capital of approximately $8.3 million as of June 30, 2026 [sec_mda · as of 2026-08-14].
- Net cash used in operations during the nine months ended June 30, 2026 was approximately $23.0 million, and the primary source of cash flow has been financing activities [sec_mda · as of 2026-08-14].
- Quarterly product revenue declined from $1,667,298 (three months ended March 31, 2026) to $1,493,788 (three months ended June 30, 2026), and gross profit margin fell from ~80% to ~67% over the same period [sec_mda · as of 2026-08-14].
From the filings
Quoted directly from source documents.
LYMPHIR commercial launch began in December 2025 and generated initial revenue.
“Product revenues for the nine months ended June 30, 2026 were $ 7,105,197, as Citius Oncology began commercial distribution of LYMPHIR in December 2025.”
SEC MD&A · August 14, 2026
Cash position as of June 30, 2026.
“At June 30, 2026, we had approximately $17.0 million in cash”
SEC MD&A · August 14, 2026
Accumulated deficit as of June 30, 2026.
“2026, we had an accumulated deficit of approximately $277.1 million.”
SEC MD&A · August 14, 2026
Phase 1 combination study of LYMPHIR with pembrolizumab was presented at ASCO 2026.
“Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), an oncology‑focused biopharmaceutical company and majority‑owned subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), today announced that University of Pittsburgh Medical Center's investigator-initiated trial evaluating LYMPHIR (denileukin diftitox-cxdl) in combination with the PD-1 immune checkpoint inhibitor pembrolizumab (KEYTRUDA®) has been selected for poster presentation at the American Society of Clinical O”
News · May 26, 2026
Risks & what to watch (3)›
Key risks
- Negative working capital — Negative working capital of ~$8.3M as of June 30, 2026, indicating short-term liquidity pressure [sec_mda · as of 2026-08-14].
- Reliance on financing — Primary cash flow source has been financing activities; net cash used in operations ~$23.0M in nine months ended June 30, 2026 [sec_mda · as of 2026-08-14].
- Declining quarterly revenue — Quarterly product revenue fell from $1.67M (Q ended Mar 2026) to $1.49M (Q ended Jun 2026) [sec_mda · as of 2026-08-14].
What to watch
- Revenue growth trajectory and gross margin trends for LYMPHIR in upcoming quarters [sec_mda · as of 2026-08-14].
- Progress of investigator-initiated Phase 1 combination study of LYMPHIR with pembrolizumab in gynecologic cancers [news · published 2026-05-26].
- European market adoption following initial shipment in April 2026 [sec_mda · as of 2026-08-14].
- Cash runway and any new financing or capital events given negative working capital and reliance on financing [sec_mda · as of 2026-08-14].
Sources: Catalysts · News · SEC MD&A · Generated October 10, 2026 · How we verify sources →
Run Citius Pharmaceuticals, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Citius Pharmaceuticals, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
D/E 1.00 · 0% dilution
Lead: Approved
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
37
Total value held
$842K
| Holder | Shares | Value |
|---|---|---|
| geode capital management, llc | 246,158 | $222K |
| vanguard capital management llc | 167,738 | $151K |
| vanguard fiduciary trust co | 77,755 | $70K |
| blackrock, inc. | 69,851 | $63K |
| asset advisory group, inc. | 59,011 | $53K |
| ubs group ag | 55,025 | $50K |
| northern trust corp | 43,974 | $40K |
| susquehanna international group, llp | 36,838 | $33K |
| lpl financial llc | 25,045 | $23K |
| state street corp | 23,271 | $21K |
Showing top 10 of 37 institutional holders of Citius Pharmaceuticals, Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 19.5%
- Days to cover
- 6.3
- Shares short
- 5,263,532
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
CTXR short interestGovernance
Frequently asked questions
What is the AI investment thesis for Citius Pharmaceuticals, Inc.?
Citius Pharmaceuticals, Inc. (CTXR) is a biopharmaceutical company whose majority-owned subsidiary, Citius Oncology, markets LYMPHIR (denileukin diftitox-cxdl) for cutaneous T-cell lymphoma, with early commercial revenue and ongoing clinical development.
What is Citius Pharmaceuticals, Inc.'s lead drug candidate?
Citius Pharmaceuticals, Inc.'s most advanced tracked candidate is LYMPHIR (Approved) for Treatment of patients with persistent or recurrent cutaneous T-cell lymphoma (CTCL).
Who is the CEO of Citius Pharmaceuticals, Inc.?
Mr. Leonard L. Mazur is the chief executive officer of Citius Pharmaceuticals, Inc. (CTXR).
Where is Citius Pharmaceuticals, Inc. headquartered?
Citius Pharmaceuticals, Inc. (CTXR) is headquartered in Cranford, NJ, United States.
What therapeutic areas does Citius Pharmaceuticals, Inc. focus on?
Citius Pharmaceuticals, Inc. develops therapies across Oncology, Dermatology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.